BridgeBio Oncology Therapeutics, Inc. Total Liabilities
BridgeBio Oncology Therapeutics, Inc. total liabilities. Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has total liabilities worth $45.37 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BridgeBio Oncology Therapeutics, Inc. (BBOT) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BridgeBio Oncology Therapeutics, Inc. (2021–2025)
Total liabilities of BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025. This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore BridgeBio Oncology Therapeutics, Inc. strategic investment ratio to see how much of total assets are deployed in long-term investments.
BridgeBio Oncology Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thor Medical ASA
OL:TRMED
|
Norway | Nkr314.10 Million |
|
Solvar Ltd
AU:SVR
|
Australia | AU$624.70 Million |
|
Hyundai Corp
KO:011760
|
Korea | ₩2.04 Trillion |
|
Dynamic Cables Limited
NSE:DYCL
|
India | Rs-4.57 Billion |
|
ICP DAS Co Ltd
TWO:3577
|
Taiwan | NT$367.73 Million |
|
SB Financial Group Inc
NASDAQ:SBFG
|
USA | $1.47 Billion |
|
Netfonds AG
XETRA:NF4
|
Germany | €83.24 Million |
|
Soosan Industries Co. Ltd.
KO:126720
|
Korea | ₩114.53 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down BridgeBio Oncology Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BridgeBio Oncology Therapeutics, Inc. asset portfolio.
Liquidity & Leverage Metrics
BridgeBio Oncology Therapeutics, Inc. Total Liabilities Ratios Explained
BridgeBio Oncology Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BridgeBio Oncology Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BridgeBio Oncology Therapeutics, Inc. (2021–2025)
The table below shows the annual total liabilities of BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $37.28 Million | +553.26% |
| 2024-12-31 | $5.71 Million | +1339.61% |
| 2023-12-31 | $396.46K | +138.18% |
| 2022-12-31 | $166.46K | +2.35% |
| 2021-12-31 | $162.64K | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more